JP6591961B2 - 真菌病原体および細菌病原体を処置するための組成物および方法 - Google Patents

真菌病原体および細菌病原体を処置するための組成物および方法 Download PDF

Info

Publication number
JP6591961B2
JP6591961B2 JP2016502812A JP2016502812A JP6591961B2 JP 6591961 B2 JP6591961 B2 JP 6591961B2 JP 2016502812 A JP2016502812 A JP 2016502812A JP 2016502812 A JP2016502812 A JP 2016502812A JP 6591961 B2 JP6591961 B2 JP 6591961B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
item
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016502812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515516A5 (cg-RX-API-DMAC7.html
JP2016515516A (ja
Inventor
アシュラフ エス． イブラヒム，
アシュラフ エス． イブラヒム，
マイケル アール． イーマン，
マイケル アール． イーマン，
スコット ジー． フィラー，
スコット ジー． フィラー，
ジョン イー． ジュニア エドワーズ，
ジョン イー． ジュニア エドワーズ，
ジョン ピー． ジュニア ヘネシー，
ジョン ピー． ジュニア ヘネシー，
Original Assignee
ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター
ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター
ノバダイム セラピューティクス， インコーポレイテッド
ノバダイム セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター, ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター, ノバダイム セラピューティクス， インコーポレイテッド, ノバダイム セラピューティクス， インコーポレイテッド filed Critical ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター
Publication of JP2016515516A publication Critical patent/JP2016515516A/ja
Publication of JP2016515516A5 publication Critical patent/JP2016515516A5/ja
Application granted granted Critical
Publication of JP6591961B2 publication Critical patent/JP6591961B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/165—Yeast isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/72—Candida
    • C12R2001/725—Candida albicans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016502812A 2013-03-15 2014-03-14 真菌病原体および細菌病原体を処置するための組成物および方法 Active JP6591961B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789091P 2013-03-15 2013-03-15
US61/789,091 2013-03-15
PCT/US2014/028521 WO2014144211A2 (en) 2013-03-15 2014-03-14 Compositions and methods for treating fungal and bacterial pathogens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019050907A Division JP2019110918A (ja) 2013-03-15 2019-03-19 真菌病原体および細菌病原体を処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2016515516A JP2016515516A (ja) 2016-05-30
JP2016515516A5 JP2016515516A5 (cg-RX-API-DMAC7.html) 2017-04-13
JP6591961B2 true JP6591961B2 (ja) 2019-10-16

Family

ID=51538308

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502812A Active JP6591961B2 (ja) 2013-03-15 2014-03-14 真菌病原体および細菌病原体を処置するための組成物および方法
JP2019050907A Pending JP2019110918A (ja) 2013-03-15 2019-03-19 真菌病原体および細菌病原体を処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019050907A Pending JP2019110918A (ja) 2013-03-15 2019-03-19 真菌病原体および細菌病原体を処置するための組成物および方法

Country Status (12)

Country Link
US (2) US10130691B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968497B1 (cg-RX-API-DMAC7.html)
JP (2) JP6591961B2 (cg-RX-API-DMAC7.html)
CN (1) CN105407915A (cg-RX-API-DMAC7.html)
AU (1) AU2014227748B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015022963A8 (cg-RX-API-DMAC7.html)
CA (1) CA2906771A1 (cg-RX-API-DMAC7.html)
EA (1) EA030005B1 (cg-RX-API-DMAC7.html)
MD (1) MD20150098A2 (cg-RX-API-DMAC7.html)
MX (1) MX2015012681A (cg-RX-API-DMAC7.html)
RU (1) RU2717306C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014144211A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
US10857216B2 (en) 2016-03-09 2020-12-08 Novadigm Therapeutics, Inc. Methods and kits for use in preventing and treating vulvovaginal candidiasis
JP7439371B2 (ja) * 2018-04-10 2024-02-28 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー－ ユーシーエルエー メディカル センター Ｃａｎｄｉｄａ ａｕｒｉｓ感染症の治療方法
EP3931325A1 (en) 2019-02-28 2022-01-05 Universidade do Minho Antisense oligomers for controlling candida albicans infections
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1133829A (en) 1978-08-24 1982-10-19 Neil J.L. Gilmour Pasteurellosis vaccines
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
JP3120860B2 (ja) 1995-06-07 2000-12-25 ファイザー・インコーポレーテッド コクシジウム症に対する卵内予防接種
ES2252785T3 (es) 1996-05-16 2006-05-16 THE TEXAS A&M UNIVERSITY SYSTEM Composiciones proteinicas fijadoras de colageno y metodos de utilizacion.
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US20060083750A1 (en) 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US8541008B2 (en) 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
CA2492826C (en) 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
US20030091593A1 (en) 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US7435871B2 (en) 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
CN101596312A (zh) 2002-05-21 2009-12-09 先灵-普劳有限公司 孢子纲物种体外培养的方法及其用途
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
RU2322241C2 (ru) 2003-11-21 2008-04-20 Пфайзер Продактс Инк. Применение антибиотиков в качестве адъювантов вакцин
US20050287146A1 (en) 2003-12-19 2005-12-29 Joseph Patti Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) * 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
WO2007126813A2 (en) * 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
MX2008013451A (es) 2006-04-17 2008-10-30 Schering Plough Ltd Organismos clostridium atenuados recombinantes y vacuna.
WO2008147847A1 (en) 2007-05-22 2008-12-04 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
CN102046197A (zh) 2008-05-29 2011-05-04 英特威国际有限公司 球虫病疫苗
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
PE20110023A1 (es) 2009-06-22 2011-01-31 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
KR20120085234A (ko) 2009-07-03 2012-07-31 로스 엔젤레스 바이오메디칼 리서치 인스티튜트 엣 하버-유씨엘에이 메디칼 센터 캔디다에 대한 능동 및 수동 면역의 표적으로서 ｈｙｒ１
LT2683419T (lt) * 2011-03-11 2018-07-25 Vib Vzw Molekulės ir būdai baltymo slopinimui ir aptikimui
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
EP2734229B1 (en) * 2011-07-22 2019-01-02 Novadigm Therapeutics, Inc. Methods and copositions for vaccinating against staphylococcus aureus
JP2014527084A (ja) 2011-09-14 2014-10-09 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター Ｈｙｒ１由来組成物およびそれを使用する処置方法
WO2014144024A1 (en) 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 compositions and methods for treating fungal and bacterial pathogens
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
US20160030533A1 (en) 2013-03-15 2016-02-04 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods of treating fungal and bacterial pathogens
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
US10857216B2 (en) 2016-03-09 2020-12-08 Novadigm Therapeutics, Inc. Methods and kits for use in preventing and treating vulvovaginal candidiasis

Also Published As

Publication number Publication date
AU2014227748B2 (en) 2019-02-14
CA2906771A1 (en) 2014-09-18
MX2015012681A (es) 2018-05-17
EA030005B1 (ru) 2018-06-29
JP2016515516A (ja) 2016-05-30
EP2968497A2 (en) 2016-01-20
WO2014144211A3 (en) 2015-11-19
US10130691B2 (en) 2018-11-20
EP2968497B1 (en) 2020-08-12
RU2015144090A (ru) 2017-04-19
MD20150098A2 (ro) 2016-02-29
EP2968497A4 (en) 2016-11-30
WO2014144211A8 (en) 2015-10-08
AU2014227748A1 (en) 2015-10-08
RU2717306C2 (ru) 2020-03-19
EA201591808A1 (ru) 2016-02-29
CN105407915A (zh) 2016-03-16
BR112015022963A2 (pt) 2017-11-14
WO2014144211A2 (en) 2014-09-18
JP2019110918A (ja) 2019-07-11
BR112015022963A8 (pt) 2018-01-16
US20160030534A1 (en) 2016-02-04
US20190030141A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
JP2019110918A (ja) 真菌病原体および細菌病原体を処置するための組成物および方法
JP6018140B2 (ja) ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
CN103998056B (zh) 用于接种抗金黄色葡萄球菌疫苗的方法和组合物
US10160790B2 (en) HYR1-derived compositions and methods of treatment using same
JP2017514873A (ja) リポ多糖を欠損する細胞構成要素をベースとしたアシネトバクター・バウマニワクチン
JP2005502314A (ja) ワクチン
WO2014144024A1 (en) Hyr1 compositions and methods for treating fungal and bacterial pathogens
US20160030533A1 (en) Compositions and methods of treating fungal and bacterial pathogens
US10590178B2 (en) Chimeric vaccine against fungal infections
JP2020028219A (ja) マラリアワクチン
AU2014370875B2 (en) Vaccine targeting IL-17A
EP2279203B1 (en) Prion epitopes and methods of use thereof
US20240277823A1 (en) Leptospiral virulence modulating proteins and uses thereof
US20220296696A1 (en) Immunogenic Antigens
EA047643B1 (ru) Слитые белки для противотуберкулезных вакцин
US20190269771A1 (en) Peptide mimotope that induces an immune response against mycobacterium tuberculosis lipoarabinomannan (lam)
US9944684B2 (en) CETP antigenic peptide and fusion protein and their composition and applications
JP5534630B2 (ja) Ｇｄ３模倣ペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190319

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190820

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190919

R150 Certificate of patent or registration of utility model

Ref document number: 6591961

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250